Form D · Biotechnology
NEVRO CORP
Menlo Park, CA · CIK 0001444380
Offering snapshot reported Jul 28, 2011 · SEC filing
- Reported sold
- $58.6M Offering amount: $58.6M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 15, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 28, 2011 | Initial | $58,604,692 | No comparison | 13 | SEC filing |
| Apr 23, 2010 | Initial | $19,999,998 | No comparison | 11 | SEC filing |
| Aug 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-163614
Series B Preferred Stock; Common Stock issuable upon conversion thereof
Source: Form D, filed Jul 28, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Konstantinos Alataris | Director, Executive |
| John Deedrick | Director |
| Michael De Mane | Director, Executive |
| Andrew Galligan | Executive |
| Bill Harrington | Director |
| Vincent Kim | Director |
| Vince Kim | Director |
| Mark Knudson | Director |
| Bill Moffitt | Director |
| Nathan Pliam | Director |
| Nick Pliam | Director |
| Jon Tremmel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4040 Campbell Avenue Suite 210
Menlo Park, CA, 94025
Menlo Park, CA, 94025